All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TY014
Therapeutic Area: Infections and Infectious Diseases Product Name: TY014
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 30, 2020
Details:
Data published in the New England Journal of Medicine demonstrate that TY014 was not only safe and well tolerated at the highest doses tested, but also completely eradicated the yellow fever virus in the bloodstream of all participants within 48 hours of infusion.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TY027
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2020
Details:
The study to be conducted by Tychan is meant to determine the safety and effectiveness of TY027, a monoclonal antibody or immune system protein that specifically targets Sars-CoV-2, the virus that causes Covid-19.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
